Biomarin Pharmaceutical (BMRN) executive compensation, 2026 proxy

Alexander Hardy, President and CEO, was paid $21.9M in 2025, up 48% from $14.9M the year before. The CEO-to-median-employee pay ratio was 109:1, on median employee pay of $201,036.

Filed
April 21, 2026
Annual meeting
June 2, 2026
Pay year
2025
Named executives
5
CEO total pay
$21.9M+48% vs prior year
CEO to median employee
109:1median $201,036
CEO pay in equity
85%$18.7M in awards
Prior say-on-pay support
93%of votes cast
2025 Total Revenues
$3.2BUp 13% year over year
VOXZOGO Revenue
$927MGrew 26% from 2024
Amicus Acquisition Value
$4.8BAnnounced in December 2025
Inozyme Acquisition Value
$270MCompleted in July 2025

How Hardy was paid

$21.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary5%Stock awards77%Option awards9%Non-equity incentive7%All other compensation2%

Named executive officers

ExecutiveTotal
Alexander HardyPresident and CEO$21,927,563
Brian R. MuellerExecutive Vice President, CFO$6,831,812
Gregory R. Friberg, M.D.Executive Vice President, Chief Research & Development Officer$7,174,583
C. Greg Guyer, Ph.D.Executive Vice President, Chief Technical Officer$5,691,680
Cristin HubbardExecutive Vice President, Chief Commercial Officer$5,713,695

What changed and why

  • $21.9MAlexander Hardy received total compensation of $21,927,563 in 2025 compared to $14,853,605 in the prior year.
  • $3.2BTotal revenues reached $3.2 billion in 2025, representing a 13% increase year over year.
  • $927MVOXZOGO revenue grew 26% to $927 million in 2025.
  • 93%Stockholders previously approved the executive compensation program with over 93% support.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.